Because genetic susceptibility to Lynch syndrome is a pathogenic variation of one of the four MMR genes (MLH1, MSH2, MSH6, or PMS2), most Lynch syndrome patients have MMR deficiency, MSI, and immune response system activation; thus, Lynch syndrome patients may be the best candidates for ICI therapy (20). The gene discussed is MSH6; the disease is mismatch repair cancer syndrome 1.